LB Pharmaceuticals (LBRX) announced the initiation of its pivotal Phase 3 trial NOVA-2 evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement
- LB Pharmaceuticals adds neuroscience leader to board, governance
- LB Pharmaceuticals appoints Lenz to Board of Directors
- LB Pharmaceuticals management to meet with Piper Sandler
- LB Pharmaceuticals Announces $100 Million Private Placement Financing